Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CARM Carisma Therapeutics	$0.24 +3.7%	$0.37	$0.14 ▼ $1.27	$9.95M	1.79	5.76 million shs	734,457 shs
EVGN Evogene	$1.31 +2.7%	$1.33	$0.95 ▼ $3.93	$7.01M	1.59	869,964 shs	15,664 shs
SDST Stardust Power	$0.40 +4.0%	$0.34	$0.14 ▼ $12.56	$24.08M	0.23	4.38 million shs	1.05 million shs
SNES Senestech	$4.68 +3.9%	$4.79	$1.30 ▼ $6.24	$22.79M	0.2	127,683 shs	73,514 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CARM Carisma Therapeutics	-4.06%	-19.59%	-40.51%	+24.00%	-81.65%
EVGN Evogene	+4.51%	-6.25%	-1.93%	+8.97%	-67.96%
SDST Stardust Power	-1.41%	-9.85%	-3.39%	-36.63%	-96.19%
SNES Senestech	-2.17%	-2.39%	-19.50%	+71.76%	-6.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CARM Carisma Therapeutics	3.0433 of 5 stars	3.4	5.0	2.7	0.8	0.6
EVGN Evogene	2.7125 of 5 stars	3.8	3.0	3.1	0.0	0.6
SDST Stardust Power	2.9243 of 5 stars	3.6	0.0	2.9	2.5	0.6
SNES Senestech	2.1181 of 5 stars	3.5	2.0	2.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CARM Carisma Therapeutics	2.71	Moderate Buy	$1.93	708.82% Upside
EVGN Evogene	3.50	Strong Buy	$3.50	167.38% Upside
SDST Stardust Power	3.20	Buy	$5.11	1,178.13% Upside
SNES Senestech	3.00	Buy	$10.00	113.90% Upside

Current Analyst Ratings Breakdown

Latest EVGN, CARM, SNES, and SDST Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	EVGN Evogene	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/11/2025	SNES Senestech	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
8/8/2025	CARM Carisma Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$1.00
8/8/2025	SNES Senestech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2025	CARM Carisma Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/22/2025	EVGN Evogene	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$5.00 ➝ $3.50

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CARM Carisma Therapeutics	$19.63M	0.51	N/A	N/A	($1.10) per share	-0.22
EVGN Evogene	$8.51M	0.83	N/A	N/A	$2.31 per share	0.57
SDST Stardust Power	N/A	N/A	N/A	N/A	($0.06) per share	N/A
SNES Senestech	$2.09M	11.04	N/A	N/A	$1.41 per share	3.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CARM Carisma Therapeutics	-$60.48M	-$1.56	N/A	N/A	N/A	-254.28%	N/A	-192.17%	11/5/2025 (Estimated)
EVGN Evogene	-$16.49M	-$2.25	N/A	∞	N/A	-211.61%	-109.96%	-38.47%	N/A
SDST Stardust Power	-$23.75M	-$0.56	N/A	N/A	N/A	N/A	N/A	-268.49%	N/A
SNES Senestech	-$6.18M	-$5.44	N/A	N/A	N/A	-289.01%	-150.93%	-111.41%	N/A

Latest EVGN, CARM, SNES, and SDST Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	SDST Stardust Power	-$0.03	-$0.06	-$0.03	-$0.06	N/A	N/A
8/7/2025	Q2 2025	SNES Senestech	N/A	-$0.87	N/A	-$0.87	N/A	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CARM Carisma Therapeutics	N/A	N/A	N/A	N/A	N/A
EVGN Evogene	N/A	N/A	N/A	N/A	N/A
SDST Stardust Power	N/A	N/A	N/A	N/A	N/A
SNES Senestech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CARM Carisma Therapeutics	N/A	0.48	0.48
EVGN Evogene	N/A	1.89	0.92
SDST Stardust Power	N/A	0.25	0.25
SNES Senestech	0.03	9.23	8.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CARM Carisma Therapeutics	44.27%
EVGN Evogene	10.40%
SDST Stardust Power	32.79%
SNES Senestech	5.19%

Insider Ownership

Company	Insider Ownership
CARM Carisma Therapeutics	6.90%
EVGN Evogene	7.40%
SDST Stardust Power	55.30%
SNES Senestech	5.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CARM Carisma Therapeutics	20	41.79 million	38.91 million	No Data
EVGN Evogene	140	5.37 million	4.97 million	Optionable
SDST Stardust Power	N/A	60.80 million	27.18 million	N/A
SNES Senestech	30	4.94 million	4.68 million	Not Optionable

EVGN, CARM, SNES, and SDST Headlines

Recent News About These Companies

Contrasting Senestech (NASDAQ:SNES) and TriSalus Life Sciences (NASDAQ:TLSI)

August 20 at 4:05 AM | americanbankingnews.com

SenesTech to Participate in the Lytham Partners 2025 Consumer & Technology Investor Summit on August 19, 2025

August 18, 2025 | prnewswire.com

SenesTech files to sell 2.26M shares of common stock for holders

August 15, 2025 | msn.com

SenesTech files to sell 2.26M shares of common stock by selling shareholders

August 15, 2025 | msn.com

SenesTech Enters New Warrant Agreements for Funding

August 14, 2025 | theglobeandmail.com

H.C. Wainwright Sticks to Their Buy Rating for SenesTech (SNES)

August 14, 2025 | theglobeandmail.com

SenesTech (SNES) Q2 Sales Jump 36%

August 14, 2025 | theglobeandmail.com

SenesTech Second Quarter 2025 Earnings: US$0.87 loss per share (vs US$3.08 loss in 2Q 2024)

August 12, 2025 | finance.yahoo.com

Equities Analysts Issue Forecasts for Senestech Q3 Earnings

August 11, 2025 | americanbankingnews.com

Senestech (NASDAQ:SNES) Upgraded at HC Wainwright

August 11, 2025 | americanbankingnews.com

SenesTech outlines path to breakeven at $1.5M quarterly revenue with Evolve driving 94% year-over-year growth

August 8, 2025 | msn.com

SenesTech Reports Second Quarter 2025 Financial Results with Record Revenue and Record Gross Profit Margins

August 7, 2025 | prnewswire.com

SenesTech Announces Closing of Warrant Exercise for $6.3 Million in Gross Proceeds

August 5, 2025 | prnewswire.com

SenesTech Announces Warrant Exercise for $6.3 Million in Gross Proceeds

August 5, 2025 | prnewswire.com

SenesTech to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

July 31, 2025 | prnewswire.com

SenesTech Raises $4.4M Through Warrant Exercise

July 4, 2025 | theglobeandmail.com

SenesTech Announces Closing of Warrant Exercise for $4.4 Million in Gross Proceeds

July 1, 2025 | prnewswire.com

SenesTech Announces Warrant Exercise for $4.4 Million in Gross Proceeds

July 1, 2025 | prnewswire.com

SenesTech, Inc. (SNES) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

SenesTech's Evolve™ Rodent Birth Control Proven in Urban Rodent Hotspots from Hong Kong to San Francisco

June 26, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN, CARM, SNES, and SDST Company Descriptions

Carisma Therapeutics NASDAQ:CARM

$0.24 +0.01 (+3.75%)

As of 03:42 PM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evogene NASDAQ:EVGN

$1.31 +0.03 (+2.67%)

As of 03:47 PM Eastern

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Stardust Power NASDAQ:SDST

$0.40 +0.02 (+4.03%)

As of 03:47 PM Eastern

Stardust Power Inc. is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.

Senestech NASDAQ:SNES

$4.68 +0.18 (+3.89%)

As of 03:46 PM Eastern

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time